Table 3 Fine and Gray’s competing-risks analysis

Age

0.968

0.959–0.978

< 0.001

0.979

0.966–0.992

0.002

Sex (M)

0.716

0.491–1.044

0.083

–

BMI

0.999

0.974–1.024

0.922

–

SOFA score at ICU admission

0.836

0.788–0.887

< 0.001

0.867

0.792–0.949

0.002

SAPS II score

0.973

0.959–0.987

< 0.001

–

Hypertension

0.648

0.498–0.843

0.001

–

Chronic ischemic heart disease

0.760

0.473–1.221

0.257

–

COPD (oxygen therapy/CPAP)

0.982

0.219–4.407

0.981

–

Chronic kidney disease (CKD)

0.692

0.303–1.582

0.383

–

CKD –dialisys

0.532

0.061–4.640

0.568

–

Diabetes

0.703

0.459–1.078

0.106

–

Chronic liver disease (MELD > 10)

0.853

0.224–3.239

0.815

–

Renal replacement therapy during ICU stay

0.274

0.142–0.531

< 0.001

0.381

0.220–0.660

0.001

Early onset VAP

0.844

0.600–1.188

0.331

–

Late-onset VAP

0.357

0.251–0.510

< 0.001

0.283

0.197–0.407

< 0.001

Lowest PaO₂/FiO₂ within 5 days^a

1.729

1.312–2.280

< 0.001

1.631

1.316–2.023

< 0.001

C_RS < 40 mL/cmH₂O within 5 days

0.538

0.350–0.826

0.005

0.488

0.317–0.752

0.001

Cardiovascular complications

0.253

0.175–0.367

< 0.001

0.277

0.181–0.423

< 0.001

Neurologic complications

0.550

0.236–1.283

0.167

0.469

0.207–1.061

0.069

Gastrointestinal complications

0.578

0.374–0.894

0.014

–

Extrapulmonary infections

0.533

0.326–0.872

0.012

–